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The c-Jun N-terminal kinase (JNK) family, with its three members JNK1, JNK2, and JNK3, is a subfamily of
mitogen-activated protein kinases. Involved in many aspects of cellular processes, JNK has been also asso-
ciatedwith pathological states such as neurodegenerative diseases, inflammation, and cancers. In oncology,
each isoform plays a distinct role depending on the context of the targeted tissue/organ, the tumor stage,
and, most likely, the signaling pathway activated upstream. Consequently, the current challenge in finding
new successful anti-JNK therapies is to design isoform-selective inhibitors of the JNKs. In this review, a
particular focus is given to the JNK inhibitors that have been developed thus far when examining 3D struc-
tures of various JNK-inhibitor complexes. Using current data regarding structure-activity relationships and
medicinal chemistry approaches, our objective is to provide a better understanding of the design and devel-
opment of selective JNK inhibitors in the present and future.Introduction
Given their role in many physiological and pathological cell
signaling pathways, protein kinases have intensively been
studied and described as ideal drug targets for cancer therapies.
Over the past decade, many small molecule kinase inhibitors
have been approved and have entered the market to treat
different types of malignancies (Zhang et al., 2009). The
mitogen-activated protein kinase (MAPK) family, which includes
extracellular signal-regulated kinases (ERKs) and c-Jun N-termi-
nal kinases (JNKs), is involved in the control of cell proliferation,
differentiation, migration, inflammation, and apoptosis (Dhillon
et al., 2007; Kim and Choi, 2010). The intracellular signaling path-
ways involving the MAPK family are often deregulated and acti-
vated in human cancers. Thus, much attention has been paid to
the design of new inhibitors of this kinase family for the treatment
of malignant disorders (Pratilas and Solit, 2010; Santarpia et al.,
2012). JNK3 is predominantly expressed in the brain, testes, and
heart (Bode and Dong, 2007), and its specific inhibition is able to
inhibit neurodegenerative diseases in animal models (Parkinson
and Alzheimer diseases) (Antoniou et al., 2011). JNK1 and JNK2
are ubiquitously expressed in tissues and can present with
similar or different functions (Davis, 2000). JNK1 inhibitors would
be of interest in metabolic diseases because animal models
treated with anti-JNK1 become resistant to food-induced
obesity (Sabio and Davis, 2010). JNK2, most often concomi-
tantly with JNK1, is involved in autoimmune diseases such as
rheumatoid arthritis and asthma (Bennett, 2006; Han et al.,
2001). JNK2 also appears to be involved in vascular pathologies
and atherosclerosis (Sumara et al., 2005).
Responsible for phosphorylating the protein encoded by the
proto-oncogene c-jun, JNK was initially proposed to be the
key mediator of cell transformation. Since this hypothesis,Chemistry & Biology 2studies have contributed to a more complete understanding of
the function of JNKs in oncogenic signaling. JNK signaling func-
tions to induce defense mechanisms that protect organisms
against a variety of situations by dually regulating stress-induced
apoptosis and autophagy (Tournier et al., 2000). According to its
positive regulation of apoptosis, a substantial body of evidence
implicates JNK proteins in tumor suppression (Davis, 2000;
Wagner and Nebreda, 2009). First, animal studies have demon-
strated that JNK1-deficient mice are highly susceptible to tumor
development (She et al., 2002; Tong et al., 2007), and more
recently, impaired JNK signaling was shown to accelerate
tumorigenesis in prostate, breast, or pancreatic cancer (Cellurale
et al., 2012; Davies et al., 2014; Hu¨bner et al., 2012). Second,
JNK can sensitize cancer cells to genotoxic stress-induced cell
death (Sau et al., 2012; Song et al., 2012; Xiao et al., 2012),
and knockdown of both JNK1 and JNK2 by small interfering
RNA impaired apoptosis in response to anticancer drugs (Oleinik
et al., 2007). The information outlined earlier indicates that JNK
can act as a tumor suppressor in different types of cancer.
On the other hand, hyperactivation of the JNK proteins has
been reported in multiple cancer cell lines and tissue samples,
and JNK can promote tumor formation or induce drug-resis-
tance pathways in a wide range of human cancers, including
hepatocellular carcinoma, cholangiocarcinoma, lung adenocar-
cinoma, colon carcinoma, or triple-negative breast cancer
(Chen et al., 2014; Das et al., 2011; Feng et al., 2014; Hui et al.,
2008; Leventaki et al., 2014; Nguyen et al., 2014; Sui et al.,
2014). In this context, JNK can act as a tumor promoter, and
its oncogenic action would be attributed to its role in positive
regulation of autophagy processes. In normal cells and during
early oncogenic transformation, autophagy is a tumor-suppres-
sive process but may act as a critical survival pathway for1, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1433
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apoptotic thresholds, the JNK-induced autophagy may serve as
a survival mechanism in many tumor cells, allowing them to
escape apoptotic or necrotic death in response to metabolic
crisis. Thus, JNK can lead to an upregulation of autophagy that
was associated with therapeutic resistance (Jia et al., 2014; Li
et al., 2009). To further complicate the understanding of the path-
ological role of JNK in oncology, recent studies have shown that
JNK1 and JNK2 present distinct, or even opposite, functions in
different types of cancer. A hyperactivation of JNK1, but not
JNK2, was observed in hepatocellular carcinoma and lung
adenocarcinoma (Chang et al., 2009a, 2009b; Takahashi et al.,
2010). In contrast, other studies have described an oncogenic
function for JNK2 in various tumor-derived cell lines and animal
models of cancer (Barbarulo et al., 2013; Ke et al., 2010). In addi-
tion, JNK1 and JNK2 exert a concomitant role in Ras-induced
tumorigenesis in lung cancer (Cellurale et al., 2011), while JNK
isoforms differentially regulate the metastatic cascade (Ebelt
et al., 2013). Finally, the double-edged sword of JNK in tumor
progression was reported in hepatocellular carcinoma, where
JNK supports tumor development in the tumor microenviron-
ment but inversely reduces the tumor burden in hepatocytes
(Das et al., 2011).
Compiling all of these findings, it is now obvious that the role of
JNKs in oncology signaling is tissue specific, cell type depen-
dent, isoform specific, and dependent on the tumor stage,
most likely, the signaling pathway activated upstream; and that
it might vary according to stress signals and other circum-
stances. Given that, biomarkers should be discovered and
used to distinguish and stratify patients who will be responders
or nonresponders to anti-JNK therapy (Cellurale et al., 2011;
Chin et al., 2012).
Consequently, designing new inhibitors of JNKs is now a very
active area of research in academic and industrial laboratories. In
this review, our objective is to provide the state of the art in the
design and development of JNK inhibitors by analyzing pub-
lished data in the fields of structural biophysics, medicinal chem-
istry, and pharmacology, as well as from the clinic. Primary focus
is given to the role of the JNKs in cancer pathology and candidate
JNK inhibitors that are or were in clinical development. Then, the
medicinal chemistry strategies are developed using the support
of X-ray crystallography data from the crystallized complexes
of JNKmembers and their inhibitors. Finally, we reserve a section
for describing the pharmacological and structural elements that
highlight the challenge and importance of designing selective in-
hibitors that can discriminate between JNK isoforms.
Past and Current JNK Inhibitors in Development
Because deregulation of the JNK pathway is suspected to be
causative of many disease states, tremendous efforts have
gone into trying to inhibit this pathway, and unsurprisingly, a
large variety of JNK inhibitors have been generated and evalu-
ated in clinical phases (Table S1 available online). Among them
are two major classes of compounds: the ATP-competitive and
ATP-noncompetitive inhibitors and peptide inhibitors (Bogoye-
vitch and Arthur, 2008). The first type of inhibitor is the exten-
sively tested reversible ATP-competitive inhibitor, such as
SP600125 and CEP-1347 (KT7515). SP600125 has been used
extensively in many in vitro and in vivo studies and has shown1434 Chemistry & Biology 21, November 20, 2014 ª2014 Elsevier Ltdefficacy in cell culture and in mouse models. Disease models,
including pharmacodynamic models, highlight not only the effi-
cacy of JNK inhibitors in controlling disease progression but
also their tolerability (Assi et al., 2006; Gross et al., 2007; Minutoli
et al., 2004). However, this class of inhibitors has varying de-
grees of toxicity and lacks the required specificity because
ATP-competitive inhibitors would indiscriminately inhibit the
phosphorylation of all JNK substrates. Consistent with these re-
sults, there are many reports of the failure of such competitive in-
hibitors in animal models. SP600125 development failed due to
the lack of selectivity among the JNK family and because this
compound was capable of inhibiting at least 13 other kinases
(Tanemura et al., 2009). Therefore, second-generation ATP-
competitive inhibitors such as CC-401 have been developed
and have shown potential antineoplastic activity. CC-401 was
developed based on the chemistry of SP600125 and is a potent
inhibitor of all three forms of JNK (inhibition constant, Ki, = 25–
50 nM); it has at least a 40-fold selectivity for JNK compared
with other related kinases. In cell-based assays, CC-401 shows
a specific JNK inhibition at concentrations of approximately
1–5 mM, and the compound has shown efficacy in renal injury
models. Unfortunately, a phase 1 clinical trial using CC-401 for
acute myeloid leukemia (NCT00126893) was discontinued, and
the development of CC-401 was stopped. Another SP600125
derivative that has been developed is CC-930. The safety of
CC-930, an antifibrotic inhibitor of JNK, was recently tested in
two phase 2 clinical trials (Plantevin Krenitsky et al., 2012). These
trials were terminated by the sponsor, citing the lack of
support for study continuation based on the benefit/risk profile
(NCT01203943 and NCT01466725). Semapimod (CNI-1493)
has a structure that is completely different from those of other
SP600125 derivatives. The mechanism of action of semapimod
may be posttranscriptional, targeting the proinflammatory cyto-
kine production regulated by MAPK (p38 and JNK) (Cohen et al.,
1996). Moreover, in vitro kinase assays revealed that the direct
molecular target of semapimod is the c-Raf protein kinase, an
upstreammodulator of the MAPK pathway. Moreover, a correla-
tion between the patient response with semapimod treatment
and the significant decrease in phosphorylation of JNK was
observed clinically (Lo¨wenberg et al., 2005). While promising
positive results from an open-label phase 2 study had been re-
ported, semapimod was ineffective in improving active Crohn’s
disease, with phlebitis presenting as a significant and dose-
limiting side effect (Dotan et al., 2010; Hommes et al., 2002).
Although semapimod is still under preclinical investigation with
studies continuing its characterization, its clinical development
is currently halted.
In addition, PGL5001 (bentamapimod, AS601245) is another
ATP-competitive inhibitor with a half maximal inhibitory concen-
tration (IC50) of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and
JNK3, respectively. Based on promising preliminary studies in
animal models of autoimmune diseases and neuronal apoptosis,
PGL5001 was first described to have therapeutic potential in
multiple sclerosis and fibrosis (Carboni et al., 2004; Halazy,
2006). Today, PGL5001 is proposed as a potential first-in-class
product for the treatment of endometriosis and is currently being
evaluated in a Phase 2 clinical trial.
With the lack of tolerability and/or benefit observed in clinical
phases in the past, the use of JNK inhibitors as therapeuticAll rights reserved
Figure 1. X-Ray-Resolved Structure of JNK3 in Complex with an ATP Analog, PDB ID: 1JNK
(A) Surface representation of the entire JNK3 structure illustrating its two kinase lobes: the N-terminal lobe in light gray and the C-terminal lobe in dark gray.
(B) Ribbon representation of JNK3 crystallized with a focus on the ATP-binding site with the G-rich loop in yellow, the C helix in red, the A loop in cyan, and the
hinge in magenta.
(C) Schematic representation of the active site with domain separation. Pale green, hydrophobic region 1 (HR1); forest green, adenosine binding region; cyan,
hydrophilic ribose region; orange, phosphate binding region; dark gray, hydrophobic region 2 (HR2); yellow, gatekeeper. All images were developed using PyMol.
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end, the current knowledge about the role of JNK signaling path-
ways in physiological and pathological states is progressing at a
rapid pace (Sabapathy, 2012). Particularly in oncology, much
work has been performed in solid and hematological cancers
to offer perspectives on the challenges faced when developing
drugs targeting JNKs.
Structural Insights into JNK Inhibition
With a large number of crystallized structures, the JNK family has
been extensively studied and their structural description is bio-
physically possible. As in almost all other tyrosine kinases, the
X-ray structure of JNKs is characterized by two distinct lobes,
the N-terminal and the C-terminal lobes (Figure 1A), that are
joined by a segment referred to as the hinge loop. The N-terminal
lobe is mainly composed of b strands and two a helices, and the
C-terminal lobe is composed of a helices. The cavity formed be-
tween the two lobes creates the kinase activation site or the ATP-
binding site where the ATP docks. Typical kinase elements are
present in JNK members (Figure 1B): the G-rich loop, which is
a relatively small loop rich in glycine residues forming the active
site roof; the C helix, which contains some of the residues that
form the active site deep pocket or selectivity pocket; the activa-
tion loop (A loop), which plays a critical role in the activation/
deactivation process; and the hinge loop, which is composed
of five residues in all JNK members: Ala(113/151)-Asp
(112/150)-Met(111/149)-Leu(110/148)-Glu(109/147) in JNK1&2/
JNK3, respectively. The hinge region often plays a major role in
inhibitor binding (Shaw et al., 2008). The ATP-binding site is
composed of five distinct domains that are characterized by
distinct chemical environments (Traxler and Furet, 1999)
(Figure 1C): (1) a hydrophobic region 1 corresponding to the
entrance pocket (HR1); (2) the adenine binding region where
the nucleobase of the ATP makes hydrogen bonds with the
hinge; (3) the hydrophilic ribose region where the sugar of the
ATP binds; and (4) the hydrophilic solvent-exposed phosphate
binding region, which is delimited from (5) the hydrophobic re-
gion 2 (HR2), which is called the selectivity pocket, as deter-
mined by the highly conserved aspartate-phenylalanine-glycine
(DFG)motif (Krenitsky et al., 2012; Scapin et al., 2003; Szczepan-
kiewicz et al., 2006).Chemistry & Biology 2New and improved JNK inhibitors are in the research and
development pipeline and have a range of different inhibitor che-
motypes. JNK inhibitors exist that belong to all of the known
classes of kinase inhibitors, including reversible and irreversible
inhibitors, ATP-competitive or -noncompetitive inhibitors, and
allosteric inhibitors. Most of the new chemical entities targeting
JNKs are type I inhibitors that are defined by their ability to
compete with and replace ATP in the ATP-binding site of the ki-
nase in its active form. A single residue named the gatekeeper
(corresponding to a methionine either in position 108 in JNK1
and JNK2 or in position 146 in JNK3) restricts access to the
HR2 selectivity pocket (Liu et al., 1998). The size and nature of
this gatekeeper residue have been shown to control kinase
sensitivity. In this regard, effective strategies for the design of
selective type I inhibitors primarily consists of targeting the
sequence variability at a given position of the ATP-binding site
or exploiting the cavity (generally the selectivity pocket, consid-
ering the gatekeeper residue) of variable sizes in different ki-
nases. Unfortunately, these strategies are not transposable to
obtain selectivity among the JNK family itself. Indeed, while the
substrate specificity for each isoform can be explained by the
presence of particular and singular nonconserved residues (Xie
et al., 1998), the ATP-binding sites of the three isoforms share
a very high identity. Therefore, designing isoform-selective
type I anti-JNK inhibitors remains a challenge.
ATP-Competitive Inhibitors of JNKs: Structure-Activity
Relationship
The intense interest in developing and improving new ATP-
competitive JNK inhibitors is exemplified by the development
of the aminopyridine-based JNK inhibitor VIII (Szczepankiewicz
et al., 2006), a trisubstituted thiophene with selectivity against
JNK3 (Bowers et al., 2011a), and novel quinazoline JNK inhibi-
tors (He et al., 2011). Because many different JNK inhibitors
have been published, we have focused our analysis on the
ATP-competitive inhibitors when crystallized with a JNK family
member and the structure-activity relationship (SAR) studies
around these structures. When analyzing the published data,
we selected molecules and categorized them into two different
groups based on their binding mode to the active site of the ki-
nase and, more specifically, to the methionine residue of the1, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1435
Figure 2. Representative Chemical
Structures of the First Series of JNK
Inhibitors
In the upper window, inhibitors crystallized with
either JNK1 (structure 1; PDB ID: 2GMX) or JNK3
(structures 2, 3, and 4; PDB IDs: 3FV8, 3PTG, and
3RTP, respectively) are represented with the
hydrogen bond allowing their interaction with the
methionine residue of the hinge. In the lower win-
dow, selected chemical structures of series 1 are
schematized with the singular structural elements
(in green) impacting the binding with JNKs.
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and can be divided into two subgroups based on the cyclic or
acyclic character of the fragment (series 1 has an acyclic frag-
ment, and series 2 has a cyclic fragment). The second group is
able to bind to the hinge by forming two hydrogen bonds, which
are adjacent for series 3 or nonadjacent for series 4.
ATP-Competitive Inhibitors that Interact with the Hinge
with Only One Hydrogen Bond
Twomain chemical fragments, either acyclic or cyclic, are able to
bind with the hinge using a hydrogen bond with the oxygen atom
of a carbonyl group.
ATP-Competitive Inhibitors Using One Hydrogen Bond
and an Acyclic Fragment: Series 1
In this first series, four ATP-competitive inhibitors, presenting
with the same binding mode to the hinge with a good IC50,
were cocrystallized with either the JNK1 or JNK3 isoforms. The
binding mode involves one crucial hydrogen bond between the
amidic carbonyl moiety present in the ligand and the hinge back-
bone (Figure 2). The residue involved in the hinge region is a
methionine in either position 111 in JNK1 or position 149 in
JNK3. TheNHof the amidicmotif of the inhibitor is oriented either
inward (Figure 2, compounds 1, 3, and 4) or outward (Figure 2,
compound 2), relative to the active site.
Using SAR studies (Bowers et al., 2011a, 2011b; Hom et al.,
2010; Liu et al., 2007; Shin et al., 2009; Szczepankiewicz et al.,
2006), the central structural elements of this series of
compounds that influence the activity of the molecule can be
highlighted (Table 1 in association with Figure 2). First, the
N-methylation of the amidic nitrogen results in the total loss of
the activity (compound 6 in comparison with compound 5 in
Table 1). For some inhibitors, this hydrogen has another signifi-
cant role: it intervenes in the intramolecular H-bond interaction
between the amidic hydrogen and the triazol nitrogen, thereby
inducing a partial planarity of the inhibitor structure (Bowers
et al., 2011a) (structure 7 in comparison with structure 8 in1436 Chemistry & Biology 21, November 20, 2014 ª2014 Elsevier Ltd All rights reservedTable 1), which, in this case, seems to
be crucial for the inhibitor activity. Most
of the inhibitors possess one CH2 group,
linking the amidic carbonyl to a heteroar-
omatic ring (HAr), HAr-1. When this CH2
group is replaced by a heteroatom such
as oxygen or nitrogen (structure 9 in
comparison with structures 11 and 12),
the activity against JNK is lost. HAr-1
can make hydrophobic interactions, asobserved between the substituted phenyl ring of the compound
1 and isoleucine in position 32 of JNK1 (Szczepankiewicz et al.,
2006). It is interesting to note that additional residues on the pro-
tein surface offer the potential for hydrogen-bonding interactions
with substituents in the 4- or 5-phenyl position (Szczepankiewicz
et al., 2006). A second HAr, HAr-2, is also linked to the NH of the
amidic function of the inhibitors. Although the heteroatom of this
HAr-2 ring does not appear to interact with the protein surface,
the position of this atom shows an impact on the inhibitory activ-
ity, as observed by comparing structure 9 with structure 10
(Figure 2).
ATP-Competitive Inhibitors Using One Hydrogen Bond
and a Cyclic Fragment: Series 2
In this series, the hydrogen bond is made between a carbonyl
group and the methionine backbone of the hinge region, as in
series 1. Series 2 is distinct from series 1 because its carbonyl
motif belongs to a ring. The crystal structure of the ligand-JNK
complexes revealed that series 2 compounds present a typical
binding mode with 1-carbonyl oxygen of the isoquinolone (com-
pounds 13 and 14), azaquinolone (compound 15; Haynes et al.,
2012), or 4-quinolone (compound 16) series interacting with the
methionine of the hinge (Figure 3). The general structure of this
series involves one CH2 group substitution in position 2 of the
central core by an aromatic ring or HAr. No interaction was indi-
cated by the modification of substituents on the phenyl group in
position 4 of the isoquinolone (Asano et al., 2008a). For isoquino-
lone, preferred substituents at position 6 are small lipophilic sub-
stituents such as chlorine or bromine (compound 18 is 100 times
more potent than compound 19 on JNK1). Based on the informa-
tion derived from the cocrystal structure of the compound 13
with JNK3 and SAR studies, further optimizations were conduct-
ed by introducingmodificationsmainly at position 2 of the isoqui-
nolone ring and introducing a polar substituent on different
positions of the benzyl moiety (Asano et al., 2008a). It was thus
demonstrated in this series that the presence of a hydrogen
bond accepting and/or donating groups in the para position of
Table 1. SAR Summary for Each Series and the Described
Compounds
Series Compound
IC50 (nM)
JNK1 JNK2 JNK3
1 1 77 160 NC
2 140 NC 160
3 32 31 25
4 3 8 6
5 350 690 NC
6 >10,000 >10,000 NC
7 830 5,000 1,500
8 >10,000 >10,000 >10,000
9 750 1,100 NC
10 >10,000 >10,000 NC
11 >10,000 >10,000 NC
12 >10,000 >10,000 NC
2 13 10 NC NC
14 9 NC NC
15 49 NC NC
16 58 219 NC
17 6 NC NC
18 8,800 NC NC
19 86 NC NC
3 20 55 350 NC
21 6 24 NC
22 13 25 57
23 NC NC 270
24 51 10 7
25 809 1,140 709
26 >10,000 >10,000 >10,000
27 420 97 16
28 NC NC 3,000
29 2,600 NC NC
30 >100,000 NC NC
31 48 NC NC
4 32 101 NC 3
33 NC NC 550a
34 400 NC 25
35 NC 120 NC
36 5,350 NC 30
37 NC NC >4,000a
38 73 NC 12
NC, not calculated.
aInhibition constant, Ki.
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proposed that this effect is more important when this substitu-
tion happens on a ramification of this position as in the terminal
carboxyl group on the para-substituent of the benzyl group of
compound 14. This could be explained by an unexpected elec-
trostatic interaction between this second group and lysine in
position 68 in JNK3 (corresponding to lysine in position 30 of
JNK1). Hydrophilic substituents on this position would mostChemistry & Biology 2likely optimize the cell potency by positively regulating the lipo-
philicity of the compound.
It is interesting to note that, while the majority of compounds
are derived from 2-benzyl isoquinolone structures, it was further
proposed that a five-membered HAr such as a 5-carbonyl pyra-
zole group on the isoquinolone position 2 (compound 17) would
be preferred relative to a six-membered ring (Asano et al.,
2008b).
A structure-based drug design using compound 16 was used
to guide the design and optimization of compounds derived from
4-quinolone (Gong et al., 2012). This study resulted in the identi-
fication of inhibitors that are able to inhibit 2- to 10-fold more
JNK1 than JNK2.
ATP-Competitive Inhibitors that Interact with the Hinge
with Two Hydrogen Bonds
ATP-Competitive Inhibitors Using Two Adjacent
Hydrogen Bonds: Series 3
A large series of inhibitors crystallized with JNK1 or JNK3mimics
the two hydrogen bonds that are made by the adenine motif of
ATP, a typical binding mode of kinase inhibitors (Scapin et al.,
2003). The two hydrogen bonds are made between the methio-
nine of the hinge and the two nitrogen atoms that are separated
by a carbon in the core of an aminopyridine, aminopyrimidine, or
purine derivative ring. The NH moiety on the backbone of the
methionine of the hinge acts as the hydrogen bond donor, with
the nitrogen atom (sp2) of the pyridine derivative ring in the inhib-
itor acting as a hydrogen bond acceptor. The hinge methionine
carbonyl interacts as a hydrogen bond acceptor, with the amine
function (sp3) substituting position 2 of the pyridine derivative
ring that acts as a donor (Figure 4).
The importance of the amino group for the binding was also
highlighted in two independent SAR studies. The first demon-
strated that the replacement of the nitrogen with another atom,
such as oxygen, by creating an ether function (compound 16
versus compound 25 in Figure 4 and Table 1, respectively)
induced a complete loss of the activity of the inhibitor (Zhang
et al., 2012). In the same way, a second SAR study showed
that the addition of a substituent replacing the hydrogen atom
on the amino group leads to a complete loss of activity (com-
pound 30 compared with compounds 29 and 31) (Liu et al.,
2007) or to a change in the orientation and the binding mode of
the compound (compound 28 compared with compound 23)
(Buckley et al., 2008). The X-ray crystal structure of the amino-
pyrimidine derivative 22 shows that the 50-chlorine atom can ste-
rically interact with the sulfur atom of the methionine at position
146 (the gatekeeper of JNK3) (Alam et al., 2007). The sulfur-p
stacking interaction between the gatekeeper sulfide and a naph-
thalene ring was also well described on compound 27 (Protein
Data Bank [PDB] ID: 3OY1; (Probst et al., 2011). It was further
demonstrated that changing the size of the heterocycle
substituting the amino group (4-piperidine in compounds 22
and 23 or 4-hydroxycyclohexyl in compounds 21 and 24) from
six- to five- or four-membered rings induced a reduction in
JNK activity, suggesting a less optimal fit of the smaller rings in
the active site. Furthermore, it was shown that compound 21 is
10 times more active than compound 20 on JNK1 and JNK2.
Palmer et al. (2013) concluded that the substitution of position
4 of the indazole, particularly with polar substituents such as1, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1437
Figure 3. Representative Chemical
Structures of the Second Series of JNK
Inhibitors
In the upper window, inhibitors crystallized with
either JNK3 (structures 13 and 14; PDB IDs: 2ZDT
and 2ZDU, respectively) or JNK1 (structures 15
and 16; PDB IDs: 4E73 and 4G1W, respectively)
are represented with the hydrogen bond allowing
their interaction with the methionine residue of the
hinge. In the lower window, selected chemical
structures of series 2 are schematized with the
singular structural elements (in green) impacting
the binding with JNKs.
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and the physical properties of the molecule. Finally, SAR explo-
ration of an aminopurine series led to the identification of the
compound 24 (the development candidate CC-930), with an
improvement in potency by introducing a tetrahydrofuranyl moi-
ety in position 9 (Krenitsky et al., 2012; Plantevin Krenitsky et al.,
2012).
ATP-Competitive Inhibitors Using Two Nonadjacent
Hydrogen Bonds: Series 4
Several inhibitors were shown to benefit from two hydrogen
bonds between two nonadjacent hydrogen bonding donors
and acceptors with the methionine of the hinge (Figure 5). A first
hydrogen bond is formed between the NH moiety of the methio-
nine residue and an aromatic nitrogen atom on the inhibitor. A
second hydrogen bond is formed between the carbonyl group
of the methionine residue and an amidic NH motif on the inhibi-
tor. As an example, the importance of the second hydrogen bond
with the amide function of the inhibitors can be observed not only
by X-ray crystallography but also by SAR analyses of the 6-ani-
linoindazole derivatives (compounds 32 versus compound 36;
Swahn et al., 2005) and pyrrole carboxamide analogs (com-
pound 33 compared with compound 37; Aronov et al., 2007).
Through a crystallographic data study and SAR analyses, it
was also illustrated that indazole-based and aminopyrazole-
urea-based inhibitors interact with the hinge very similarly (com-
pounds 34, 35, and 38). A particular case is observed with
compound 35 (Shaw et al., 2008), which shares the two
hydrogen bonds commonly established by this series with the
methionine of the hinge and binds with a third hydrogen bond
to the hinge (with the glutamate in position 109 of JNK2). This
hinge binding mode is also similar to the one observed for 6-ani-
linoindazoles with JNK3 (PDB ID: 2B1P; Scapin et al., 2003).
ATP-Competitive Inhibitors of JNKs: Summary of
Structural Elements and Binding Modes for Each Series
From the structural and SAR analyses of the four chemical
series, a common binding mode for the compounds in each1438 Chemistry & Biology 21, November 20, 2014 ª2014 Elsevier Ltd All rights reservedseries can be proposed; a summarized
scheme is proposed in Figure 6. For the
first series, a central amide function binds
to the hinge by its carbonyl group and
acts as a linker between two HArs
(Figure 6, series 1). While the first HAr
(HAr-1) lies outside the active site where
it can make hydrophobic interactions,
the second HAr (HAr-2) takes refugein the adenosine pocket. For the second chemical series, all of
the ligands share a central quinolone derivative ring substituted
on positions 2, 3, and, 4 and less frequently on position 6
(Figure 6, series 2). The substituent in position 2, either a five-
or a six-membered ring linked to the quinolone ring with a CH2
linker, and the substituent in position 3 lie together in the HR1 re-
gion of the active site. Finally, position 4 is substituted by a
phenyl ring that interacts with the hydrophilic sugar region. For
the third series, the central entity is made of an amino group
linked to a HAr-2 that resides in the adenine binding region. If
the HAr-2 is an aminopyridine or aminopyrimidine ring, position
4 is usually substituted by a HAr-3 that constantly appears to
take refuge in the sugar-binding region. If the HAr-2 is a purine
derivative, the HAr-3 is linked in position 5. The substituents of
the HAr-3 (R1 in the series 3 in Figure 6) come into contact
with the selectivity pocket. The HAr-2 is also amino substituted
(with or without a linker) by a HAr-1 that lies within the solvent-
exposed region (Krenitsky et al., 2012). For the fourth series, it
was more difficult to establish obvious SAR rules. A central com-
mon binding mode can be proposed with a common skeleton
composed of a central aromatic ring or a HAr (five- or six-
membered ring) supporting two substituents in themeta position
relative to each other. The first substituent is commonly a pyra-
zole or an indazole ring that implicates the N1 atom (sp
2) in the
first hydrogen bondwith themethionine of the hinge. The second
substituent is a substituted amide function that involves the
nitrogen in the second hydrogen bond with the methionine of
the hinge. It is also interesting to note that the carbonyl group
of the amide function can take two possible orientations (as
described for the first series).
Designing Selective Inhibitors that Discriminate
between JNK Isoforms: A Pharmacological and
Structural Point of View
All of the intensive research and new findings regarding JNK
functions make the limited success of JNK inhibitors that had
entered clinical trials more understandable and predictable. In
Figure 4. Representative Chemical
Structures of the Third Series of JNK
Inhibitors
In the upper window, a selection of inhibitors
crystallized with either JNK3 (structures 22, 23,
and 24; PDB IDs: 2P33, 3CGF, and 3TTI, respec-
tively) or JNK1 (structures 20 and 21; PDB IDs:
4HYS and 4HYU, respectively) are represented
with the hydrogen bond allowing their interaction
with the methionine residue of the hinge. In the
lower window, selected chemical structures of
series 3 were selected to illustrate the structural
elements (in green) impacting the binding with
JNKs (compounds 25, 27, and 28 were also
crystallized with JNK3; PDB IDs: 3V6S, 3OY1, and
3CGO, respectively).
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context of tissue-dependent expression and role of the JNKs, or
even the pathological significance of each isoform. Conse-
quently, the lack of efficacy and the unpredicted side effects
observed in these clinical trials are, most likely, due to the lack
of an identification and selection of a subset of patients who
would respond positively to anti-JNK therapy. Hence, while the
identification of biomarkers that would allow for the stratification
of patients still remains a challenge, the generation of JNK1-,
JNK2-, and JNK3-specific inhibitors may be required to tackle
the problem of inhibitor specificity. The beneficial effect of selec-
tively targeting JNK is demonstrated by the positive results that
have already been obtained with the peptide D-JNKI-1 (XG-102,
AM-111) (Davis and Dickens, 2002; Dickens et al., 1997). Specif-
ically designed to target JNK1, the inhibitory action of D-JNKI-1
peptide (a cell-permeable JNK inhibitor) is fundamentally dif-
ferent those that of classical small chemical inhibitors because
it does not inhibit JNK’s enzymatic activity but selectively blocks
access to many of its substrates by a competitive mechanism
(Borsello et al., 2003). This cell-permeable peptide inhibitor
offers interesting possibilities for different therapeutic applica-
tions (Kersting et al., 2013; Sclip et al., 2014; Wang et al.,
2003). After the successful completion of phase 1 and 1b clinical
trials, a phase 2 study will be started for application in ophthal-
mology and in severe inner ear disorders. These very promising
results suggest that, as expected, a higher compound selectivity
for JNKs, relative to the other kinase families and the JNK family
isoform specificity, results in higher clinical benefits. Thus, spec-
ificity is a key issue that needs to be properly evaluated for the
development of successful JNK inhibition therapies and for
JNKs to continue to be considered attractive therapeutic targets
through the development of selective JNK inhibitory molecules.
In data from the literature, each compound of the series
described in this review has shown a pan-JNK activity with
selectivity against other MAPK family members and/or an
obvious selectivity against one or two JNK isoforms relative toChemistry & Biology 21, November 20, 2014 ªthe others. One of the fundamental bases
of the pan-JNK selectivity against other
kinases—and, more specifically, against
MAPK—is the conformation of the hinge
methionine carbonyl group, which is quite
unique in JNKs relative to other kinases.
At this position, the carbonyl residue isgenerally oriented toward the active site, clashing with the small
molecule electronegative groups, whereas this carbonyl group is
oriented outside the active site in JNKs, which allows small inhib-
itors with well-defined motifs to interact with this active site
comfortably (Haynes et al., 2012). More challenging are the
design and understanding of the selectivity that is observed
against isoforms within the JNK family, despite the conservation
of the ATP-binding site across these isoforms. In series 1, ana-
logs of molecules 3 and 4 were shown to be five to ten times
more potent inhibitors of JNK1 and JNK3 than of JNK2 (Bowers
et al., 2011a, 2011b). In series 2, analogs of molecule 16 pre-
sented a reasonable selectivity for JNK1 compared with JNK2
(Gong et al., 2012). In series 3, molecules with high selectivity
for JNK3 compared with JNK1 were described (Swahn et al.,
2006). More specifically, the nature of the substituents and their
orientation (R1 substituents in series 3 of Figure 6) influence the
activity and the selectivity between JNK isoforms and against
other kinases. As an example, by targeting the selectivity pocket,
the naphthalene of compound 27 and its analogs are highly
selective for JNK2 and JNK3, with four of them highly selective
against only JNK3, relative to JNK1 (Probst et al., 2011). Simi-
larly, analogs of compound 24 have shown some selectivity for
JNK3 and JNK2 relative to JNK1 (Krenitsky et al., 2012; Plantevin
Krenitsky et al., 2012). In series 4, molecules 32 and 38 exhibit a
high potency for JNK3 inhibition relative to JNK1. It was pro-
posed that some molecules of series 4 could cause a movement
of the gatekeeper methionine (position 146 of JNK3) side chain
(Kamenecka et al., 2009), allowing the N-phenyl urea group of
the pyrazoles (compound 34) and the 5-anilinophenyl substituent
on the indazoles (compound 38) to bind the hydrophobic region 2
(the selectivity pocket). According to this suggestion, it was
demonstrated that, in JNKs, the main chain of the gatekeeper
(Figure 2) is relatively labile for the three isoforms, particularly
for JNK3, which demonstrated the leading capacity to accom-
modate inhibitors in its selective pocket by a shift of 2 A˚. This
induced fit binding to JNK3 would be more favorable than that2014 Elsevier Ltd All rights reserved 1439
Figure 5. Representative Typical Chemical
Structures of the Fourth Series of JNK
Inhibitors
In the upper window, a selection of inhibitors
crystallized with either JNK3 (structures 33, 32,
and 34; PDB IDs: 2OK1, 2B1P, and 3FI2, respec-
tively) or JNK2 (structure 35; PDB ID: 3E7O) are
represented with the hydrogen bond allowing their
interaction with the methionine residue of the
hinge. In the lower window, selected chemical
structures of series 4were selected to illustrate the
structural elements impacting the binding with
JNKs (compound 38 was also crystallized with
JNK3; PDB ID: 3FI3).
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sequence differences in their selectivity pocket (Swahn et al.,
2005). The leucine in position 144 of JNK3 and JNK2, instead
of the bulky isoleucine in position 106 of JNK1, should play an
especially crucial role in conferring a more favorable induced
fit to JNK3 and JNK2 (Probst et al., 2011; Swahn et al., 2006).
To conclude, with crystal structures and SAR analysis, three
main inhibition profiles are obviously observed: first, compounds
that concomitantly inhibit JNK1 and JNK3with selectivity against
JNK2; second, a concomitant inhibition of JNK2 and JNK3 with
selectivity against JNK1; and third, an inhibition profile that con-
cerns compounds with a unique JNK3 selectivity (Probst et al.,
2011).
Conclusions
It is essential to take into close consideration which JNK proteins
are beneficial targets and, more important, what effects small
molecule inhibitors of JNKs have on physiological processes.
Accumulating evidence supports a role for the JNK proteins in
the pathogenesis of different solid and hematological malig-
nancies and highlights themany challenges and scientific oppor-1440 Chemistry & Biology 21, November 20, 2014 ª2014 Elsevier Ltd All rights reservedtunities in the targeting of JNKs in cancer
(Bubici and Papa, 2014). A number of
ATP-competitive and ATP-noncompeti-
tive JNK inhibitors have been developed,
but they have several limitations, such asa lack of specificity and cellular toxicity. With the understanding
that JNK isoforms act differently depending primarily on the tis-
sue and the pathological state, most of the drug design efforts
have thus been undertaken to find isoform-selective com-
pounds. An analysis of the literature and X-ray crystal structures
illustrated, as in other kinase inhibitors, the role of the binding
moiety to the kinase hinge region. By also using SARs, several
binding modes of JNK inhibitors can be drawn involving either
one or two hydrogen bonds within the hinge. Regardless of the
binding mode observed, all of these inhibitors are highly potent
against the JNK family members. Therefore, some research
has demonstrated that finding isoform selectivity is possible,
notably by targeting the HR2 region. Most of the efforts directed
at selectivity were focused on the inhibition of JNK3 because this
isoform is primarily expressed in the brain and is an attractive
target for neurodegenerative diseases. Because it has been
proven that selectivity for JNK3 is possible, many studies have
attempted to determine how to find selectivity for the two other
isoforms. In most of the oncology indications, the inhibition of
JNK3 should be avoided. The decision to inhibit and target either
JNK1 or JNK2 should be taken in a manner that is dependent onFigure 6. Schematic Representation of the
Four Different Series of Categorized ATP-
Competitive JNK Inhibitors
The binding mode of the four series of compounds
to the methionine of the hinge is represented using
hydrogen bonds that are symbolized by a dotted
line. The different parts of each structure are color
coded. The central scaffold that interacts with the
hinge and the adenine binding region is repre-
sented in red. The part of the molecule in blue
occupies the ribose region. The green and optional
orange parts of the ligand lie in the hydrophobic
regions 1 and 2 (HR1 and HR2, respectively).
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Reviewthe knowledge of mutation, expression, and activation states of
both isoforms in the targeted cancer. While this review was
focused on ATP-competitive inhibitors, it is well known that other
strategies would also allow for the development of isoform selec-
tivity. We can mention inhibitors that are able to bind to the ATP-
binding site of JNK in its inactive form (also known as DFG-out
state) and the development of peptides that bind to the substrate
pocket or covalent inhibitors that benefit from the presence of a
particular cysteine in the kinase site as the success of such alter-
native approaches.SUPPLEMENTAL INFORMATION
Supplemental Information includes one table and can be found with this article
online at http://dx.doi.org/10.1016/j.chembiol.2014.09.007.
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